UNSPSC 51421507: Timobesone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31FO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LGO8R495QW, chemically known as s-methyl 9-fluoro-11beta,17-dihydroxy-16beta-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-acetate but more generally known as timobesone acetate, which bears US NIH Compound Identifier 3033679. Most nations, for tariff and trade purposes, schedule timobesone acetate under HS 29372200 and SITC 54153.

As of Q4 2014, TIMOBESONE ACETATE remains US FDA's Preferred Term for this commodity. Timobesone acetate bears US NLM identifiers UMLS ID C0637015 and NCI Concept Code C90957. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SC)OC(=O)C)C)O)F)C.

UNSPSC 51421507 Timobesone acetate is a Commodity code nominally tracking a specific pharmaceutical ingredient, but the recent state and local activity tagged to this code does not reflect pharmaceutical procurement under its abstract name. Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems — a public health supply need distinct from timobesone acetate itself. The mismatch signals that this code shows little relevant recent activity aligned with its stated scope; the single recent opportunity reflects a tagging or classification drift rather than active procurement demand for the pharmaceutical ingredient the code nominally describes.

Seminole County, Florida remains the only issuing body with a recent opportunity in the source record. The IFB (Solicitation Number IFB60459723LAS) was posted June 30, 2026, with a response deadline of July 26, 2023, and calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract offers an initial two-year term with an optional one-year renewal and requires vendors to comply with E-Verify, drug-free workplace certification, and federal compliance standards including the Clean Air Act and Federal Water Pollution Control Act, with potential FEMA funding oversight. Given the narrow recent activity and the disconnect between the code's pharmaceutical scope and actual purchasing behavior, this code warrants limited near-term focus for firms pursuing state and local health or public safety supply contracts.